Articles tagged with 'Launch' | BIOTRONIK

BIOTRONIK - Archive (Launch)

2020
07
September
2020
| 08:45 Europe/Amsterdam
BIOTRONIK today announced European market release of the Passeo®‑35 Xeo PTA (percutaneous transluminal angioplasty) balloon catheter. Compared to other available PTA balloons1, the device offers physicians improved crossability, excellent trackabilit...
Read more
21
February
2020
| 14:11 Europe/Amsterdam
BIOTRONIK has announced CE Mark certification for the Orsiro® Mission drug-eluting stent (DES) system. The next generation of the company’s ultrathin strut Orsiro DES provides higher deliverability than other contemporary stents.1 Orsiro Mission is n...
Read more
2019
08
July
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced FDA clearance of the BIOMONITOR III injectable cardiac monitor (ICM). BIOMONITOR III is designed to document suspected arrhythmia or unexplained syncope with increased clarity, enabling fast diagnosis and appropriate treatme...
Read more
29
April
2019
| 00:00 Europe/Amsterdam
BIOTRONIK announced today the availability of its Plexa ProMRI S DX lead, with DF4/IS-1 connector in Europe and the US. The lead is an extension of BIOTRONIK’s Plexa family. Together with the new lead and recently launched Acticor/Rivacor ICD and CRT...
Read more
29
April
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices. Leading electrophysiologists throughout the United States are now treating patients with the new implantable cardioverter defi...
Read more
22
January
2019
| 00:00 Europe/Amsterdam
BIOTRONIK presented the innovative Pulsar-18 T3 stent system for the first time during LINC 2019 in Leipzig this week. The Pulsar-18 T3 system is a unique combination of three technologies for an improved implantation procedure. The 4-French low p...
Read more
2018
22
January
2018
| 00:00 Europe/Amsterdam
BIOTRONIK announced today market approval for its Orsiro1 coronary drug-eluting stent (Orsiro DES) by the Japanese Ministry of Health. This was supported by the positive 12-month outcomes of the BIOFLOW-IV clinical study which were presented at the 8...
Read more